Metabolic dysfunction-associated steatohepatitis — evidence across compounds
Every compound the Institute assesses in metabolic dysfunction-associated steatohepatitis, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in metabolic dysfunction-associated steatohepatitis, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| SemaglutideGLP-1 receptor agonist (acylated, long-acting) | Resolution of steatohepatitis without worsening of fibrosis in 62.9 % versus 34.3 % with placebo at 72 weeks | difference 28.7 percentage points (95 % CI 21.1 to 36.2) | Moderate | 1 |
| RetatrutideTriple GIP, GLP-1 and glucagon receptor agonist (acylated) | Liver-fat reduction exceeding 80 % relative at higher doses in a phase 2 imaging substudy | substudy; MRI-PDFF endpoint | Low | 1 |
| SurvodutideDual glucagon and GLP-1 receptor agonist (acylated) | Histological improvement in fibrosis without worsening of steatohepatitis in 34.5 % at 4.8 mg versus 22.4 % with placebo at 48 weeks | phase 2; wide confidence limits | Low | 2 |
| TesamorelinGrowth-hormone-releasing hormone analogue | Liver fat fraction reduced by 4.1 percentage points versus 0.9 with placebo at 12 months in people with HIV and hepatic steatosis | estimated difference −3.2 percentage points (95 % CI −5.5 to −0.9) | Low | 1 |
| TirzepatideDual GIP and GLP-1 receptor agonist (acylated) | Resolution of steatohepatitis without worsening fibrosis in 44–62 % across doses versus 10 % with placebo at 52 weeks | phase 2; 10 mg difference 44.4 percentage points (95 % CI 25.6 to 63.2) | Low | 1 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
- Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.